Leading BioSciences Receives IND Clearance for Phase 2 COVID-19 Study
Excerpt from the press release:
“CARLSBAD, Calif., May 15, 2020 (GLOBE NEWSWIRE) — Leading BioSciences, Inc. (LBS), a drug development company focused on improving human health through therapeutic protection of the intestinal mucosal barrier, today announced the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for a phase 2 study of its lead investigational drug, LB1148 for the “treatment of pulmonary dysfunction associated with COVID-19 pneumonia.” The study will include 120 hospitalized adult patients with respiratory dysfunction due to COVID-19.”
Click the button below to read the press release:
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?